Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nattokinase Plus is an oral dietary supplement product developed and marketed by DaVinci Laboratories for cardiovascular and circulation support. It is a combination nutraceutical containing nattokinase as the principal fibrinolytic enzyme, together with serratiopeptidase and rutin. The product is positioned to support healthy blood flow, fibrin turnover, capillary integrity, and vascular health rather than as an FDA-approved therapeutic for a specific disease. Mechanistically, nattokinase is generally described as a proteolytic enzyme with fibrinolytic activity that may promote breakdown of fibrin and support endogenous thrombolytic balance, while serratiopeptidase is a proteolytic enzyme often marketed for complementary protease activity and rutin is a flavonoid antioxidant used to support capillary strength and vascular function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Nattokinase Plus.